REG - HealthBeacon PLC HealthBeacon - HBCN - New Client Additions

ViatrisAnnouncement

10/02/2022 15:10

For best results when printing this announcement, please click on link below:
http://newsfile.refinitiv.com/getnewsfile/v1/story?guid=urn:newsml:reuters.com:20220210:nRSJ3398Ba&default-theme=true

RNS Number : 3398B  HealthBeacon PLC  10 February 2022

10 February 2022

 

HealthBeacon adds five further pharmaceutical and national healthcare systems
to its client base

 

HealthBeacon plc ("HealthBeacon" or the "Company"), the leading digital
therapeutics company that develops products for managing injectable
medications for patients in the home, is pleased to announce it has added a
further five clients to date in 2022, in addition to its 18 clients at the
time of IPO in December 2021.

The new clients include three pharmaceutical companies and two programmes
through the UK's National Health Service (NHS) and the Irish Health Service
Executive (HSE). These additions will further strengthen the Company's
customer base which now includes Amryt, Novartis, NHS, HSE, Sanofi, Accord
Healthcare, Clonmel Healthcare, Teva, Viatris, and AbbVie. The Company remains
focused on expanding its client base within Pharmaceutical Companies,
Specialty Pharmacy, Healthcare Organisations and Governments and deepening its
existing relationships.

These new agreements and continued rollout of its technology and services
through pharmaceutical companies and governments underpins HealthBeacon's
target of 100,000 units by the end of 2023 and the potential for further
significant growth in the medium term.

Jim Joyce, CEO, and co-founder of HealthBeacon commented:

"These new client wins add to the very significant momentum in the business as
leading pharma companies and health systems adopt our technology.  We are
pleased to be working with some of the most high-profile and innovative global
health organisations across our key markets.

The Company's leading injectable medication management platform alongside its
highly innovative patient services technology platform give us leadership in
all markets we serve. Unfortunately, one in two patients on chronic and
critical self-administered injectable medications fail to initiate treatment
or discontinue therapy within the first 12 months. HealthBeacon's technology
and services supports those patients and enhances their likelihood of success
on these important medications, something that is increasingly recognised by
many of the world's largest healthcare organisations"

 

 Enquiries:

 HealthBeacon:                                   Investor.Relations@HealthBeacon.com

 Laurence Flavin

 Goodbody (Euronext Growth Adviser and Broker):  +353 (1) 667 0420

 David Kearney
 Stephen Kane

 Drury (Public Relations):
 Billy Murphy                                    +353 (0) 87 231 3085
 Cathal Barry                                    +353 (0) 87 227 9281

 

Ends

 

About HealthBeacon

Headquartered in Dublin, HealthBeacon is an Irish digital therapeutics company
that develops products for managing injectable medications for patients in the
home. The HealthBeacon Injection Care Management System tracks adherence and
persistence with medication schedules through the provision of medication
management reminders, safe and sustainable sharps disposal devices,
educational tools, and artificial intelligence (AI) driven data analytics. The
Company operates in 17 countries primarily across Europe, North America and
the United Kingdom employs more than 50 people and has obtained more than 30
design and utility patents. Peer reviewed evidence supports a 19% improvement
in therapy persistence by patients, which improves clinical outcomes and
significantly improves efficiency in health systems. The Company's mission is
to become the world's leading digital therapeutics platform for injectable
medications.

 

This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact
rns@lseg.com (mailto:rns@lseg.com)
 or visit
www.rns.com (http://www.rns.com/)
.

RNS may use your IP address to confirm compliance with the terms and conditions, to analyse how you engage with the information contained in this communication, and to share such analysis on an anonymised basis with others as part of our commercial services. For further information about how RNS and the London Stock Exchange use the personal data you provide us, please see our
Privacy Policy (https://www.lseg.com/privacy-and-cookie-policy)
.   END  ISEBSGDDDGBDGDG